Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 92,700 shares, a decrease of 59.8% from the February 29th total of 230,700 shares. Based on an average daily trading volume, of 1,590,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.2% of the shares of the stock are short sold.
Clearmind Medicine Price Performance
Shares of CMND traded down $0.02 during mid-day trading on Thursday, reaching $1.15. The company had a trading volume of 35,550 shares, compared to its average volume of 1,670,891. Clearmind Medicine has a twelve month low of $0.92 and a twelve month high of $50.10. The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average is $1.42 and its 200-day moving average is $3.13.
Clearmind Medicine (NASDAQ:CMND – Get Free Report) last issued its earnings results on Monday, March 18th. The company reported ($0.90) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Clearmind Medicine
About Clearmind Medicine
Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.
Further Reading
- Five stocks we like better than Clearmind Medicine
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Value Stocks Too Small For Buffett’s Portfolio
- High Flyers: 3 Natural Gas Stocks for March 2022
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Use the MarketBeat Stock Screener
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.